Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Retina, Business and Innovation

Quantum Leap?

At a Glance

  • Dysfunction and death of retinal cells, and consequent vision loss, can be inhibited by direct electrical stimulation of vulnerable cells in the visual pathway
  • We achieve this effect not by invasive, bulky implants that generate unnatural visual stimuli, but by intravitreal injection of a colloidal suspension of nanoparticle devices that support natural vision
  • These “quantum dots” diffuse into the retina where they transduce visible light energy into electricity, thereby triggering action potentials in adjacent neural cells and preserving function
  • Our initial field of focus is retinitis pigmentosa; we are following encouraging Phase I results with a controlled, 15-patient clinical trial, expected to be complete by the end of 2020.

While I have been involved in ophthalmology since 1999, my career in the medical device industry started with CAT scanners as well as ultrasound machines and other devices in fields including cardiology, critical care and anesthesia. I migrated into ophthalmology in the laser therapeutic space as President of Coherent Medical, and have been in the field ever since. I’m now at a point in life where I try to spend my time only on developing new technologies that will make a significant difference to patients – opportunities that can truly change healthcare for the better. With some much recent innovation, where might we find such step-change opportunities in ophthalmology today?

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

0114-601-ATA-Jim Taylor

Jim Taylor

President and CEO, 2CTech Corp, San Francisco, USA.

Previously, Jim as held the positions of Head of Research & Development and Head of Marketing of Carl Zeiss Meditec AG, and was the Chief Executive Officer and President of Carl Zeiss Meditec, Inc. until joining Oraya Therapeutics. A former US Navy submarine commander, Jim has had a wide range of management experiences, and brings them together in this column for The Ophthalmologist.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register